Safety and immunogenicity of vaccines against SARS-CoV-2
Archivos Venezolanos de Farmacologia y Terapeutica
; 40(9):946-952, 2021.
Article
in English
| EMBASE | ID: covidwho-2067022
ABSTRACT
The mortality rate estimated by the WHO worldwide for CO-VID-19 has been 5.7%, much higher than other communicable infectious diseases, so it is essential to apply a vaccine to the population to reduce the viral spread, according to the WHO there are 23 projects in clinical phase stage III, such as vaccines ChadOx1, nCov-19, Gam-COVID-Vac, CoronaVac that show promising results in research published by The Lancet Infection Diseases journal, for which we consider correlating the three vaccines and determining which is safer, generates greater im-munogenicity and less reactogenicity in volunteer participants, for which we conducted a review bibliography and a meta-anal-ysis of high impact scientific articles, concluding that the three vaccines generate a rapid and intense immune response against SARS-CoV-2, neutralizing antibodies had elevated titers in participants at 28 days, who increased and remained stable with a second dose, although each of them have been tested in different numbers and populations, applying recombinant adenovi-ral vectors and chemically inactivated virions with adjuvant and placebo for which they are totally different but with the same purpose to generate memory antibodies against SARS-CoV-2. Copyright © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.
ChAdOx1-S; Gam-COVID-Vac; SARS-CoV-2; Sinovac's Coro-navac; Vaccine; adult; article; communicable disease; human; immune response; immunogenicity; memory; mortality rate; nonhuman; Severe acute respiratory syndrome coronavirus 2; virion; adjuvant; coronavac; neutralizing antibody; placebo; sputnik v vaccine; vaxzevria
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Archivos Venezolanos de Farmacologia y Terapeutica
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS